Novo Nordisk Shares Face Mounting Pressure as Analyst Warns of Further Declines

A leading financial institution has issued a stark warning for investors in Novo Nordisk, suggesting the Danish pharmaceutical giant’s stock may continue its precipitous fall. Despite a year-to-date loss of approximately 50% in market capitalization, Jefferies analysts believe the bottom has not yet been reached.

In a move that dampened market sentiment, Jefferies resumed coverage of Novo Nordisk with a stark “Underperform” rating. Analyst Michael Leuchten set a price target of 270 Danish Krone (DKK), implying a potential further decline of about 14% from current trading levels. The firm’s analysis points to two core concerns: the continued absence of a valuation floor despite the year’s severe losses and looming structural Read more...